Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05806099
Other study ID # MBS303-CT101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 28, 2023
Est. completion date November 2026

Study information

Verified date March 2023
Source Beijing Mabworks Biotech Co., Ltd.
Contact Yuqin Song, Doctor
Phone 8610-88196118
Email SongYQ_VIP@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date November 2026
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Able and willing to provide written informed consent and to comply with the study protocol. 2. Adult patients, =18 years of age; 3. CD20+ B-cell Non-Hodgkin Lymphoma who have relapsed after or failed to respond to at least one prior treatment regimen with an anti-CD20 monoclonal antibody and for whom there is no available therapy expected to improve survival; 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 5. Life expectancy =3 months; 6. Measurable disease, defined as at lease one bi-dimensionally measurable nodal lesion, defined as >1.5 cm in its longest dimension, or at least one bi-dimensionally measureable extranodal lesion, defined as >1.0 cm in its longest dimension 7. Adequate hematologic, hepatic, and renal function. Exclusion Criteria: 1. Chronic lymphoblastic leukemia, Burkitt lymphoma or lymphoplasmacytic lymphom; 2. History of central nervous system (CNS) lymphoma or other CNS disease; 3. Participants with known active infection, including bacterial, viral, parasite, mycobacterial, or other infections (excluding nail bed fungal infections); 4. Surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, tumor embolization, or other antitumor therapy within 28 days prior to the first MBS303; 5. Active or suspected autoimmune diseases; 6. Known severe allergic reaction or/and infusion reaction to monoclonal antibody; 7. Evidence of significant, uncontrolled concomitant disease; 8. Major surgery within 28 days prior to the first MBS303 administration or expected to undergo major surgery during the study treatment; 9. History of another invasive malignant tumors in past 3 years; 10. Participant with history of confirmed progressive multifocal leukoencephalopathy (PML); 11. Severe hemorrhagic diseases such as hemophilia A, hemophilia B, vascular hemophilia, or spontaneous bleeding requiring blood transfusion or other medical intervention; 12. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (including HBsAg, HBcAb positive with abnormal HBV DNA or HCV RNA); 13. Pregnant or lactating women; Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) while participating in the study; 2) for at least 12 months after discontinuation of all study treatments.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MBS303
Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg ~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7. Phase ?: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7

Locations

Country Name City State
China Beijing Cancer Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Mabworks Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I:Percentage of Participants with Adverse Events (AEs) Percentage of Participants with AEs and SAEs Assessed by NCI CTCAE v5.0 From Baseline up to approximately 13 months
Primary Phase I:Incidence of Dose Limiting Toxicities (DLTs) From Baseline up to 3 weeks
Primary Phase I:Maximum Tolerated Dose (MTD) of MBS303 From Baseline up to 3 weeks
Primary Phase I:Recommended Phase ? Dose (RP2D) of MBS303 From Baseline up to 4 years
Primary Phase ? :Antitumor activity as measured by the objective response rate (ORR) Up to approximately 2 years
Secondary Phase I and ? :Pharmacokinetics: AUC The area under the curve (AUC) of serum concentration of MBS303 after the administration up to approximately 1 year
Secondary Phase I and ? :Pharmacokinetics: t1/2 Half-life (t1/2) of MBS303 after administration up to approximately 1 year
Secondary Phase I and ? :Pharmacokinetics: CL Clearance (CL) of MBS303 after administration up to approximately 1 year
Secondary Phase I and ? :Pharmacokinetics: Vd Volume of distribution (Vd) of MBS303 after administration up to approximately 1 year
Secondary Phase I and ? :Efficacy: Complete Response Rate (CRR) of MBS303 as Assessed Using Standard Criteria for NHL Up to approximately 2 years
Secondary Phase I and ? :Efficacy: Duration of Response (DOR) of MBS303 as Assessed Using Standard Criteria for NHL Up to approximately 2 years
Secondary Phase I and ? :Efficacy: Progression-Free Survival (PFS) of MBS303 as Assessed Using Standard Criteria for NHL Up to approximately 2 years
Secondary Phase I and ? :Efficacy: Overall Survival (OS) of MBS303 Up to approximately 2 years
Secondary Phase I and ? :Immunogenicity: Anti-Drug Antibodies (ADA) to MBS303 Up to approximately 1 year
Secondary Phase I :Efficacy: ORR Up to approximately 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT01878890 - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. Phase 1
Completed NCT04152148 - A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients Phase 1
Recruiting NCT05096234 - 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma Phase 2
Recruiting NCT05191225 - Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study Phase 4
Recruiting NCT05623982 - Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03664635 - MB-CART20.1 Lymphoma Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Terminated NCT01699581 - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant Phase 2
Completed NCT01763398 - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study N/A
Completed NCT01205503 - Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00969462 - Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Phase 4
Completed NCT00659425 - CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma Phase 1
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Completed NCT00608907 - An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) Phase 1
Completed NCT00533728 - Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma Phase 1
Withdrawn NCT00577161 - Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL Phase 3
Completed NCT00581646 - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance N/A
Completed NCT00430352 - MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Phase 4